CN116270922B - Prescription for eliminating turbid pathogen, resolving masses and removing arthralgia and application thereof - Google Patents
Prescription for eliminating turbid pathogen, resolving masses and removing arthralgia and application thereof Download PDFInfo
- Publication number
- CN116270922B CN116270922B CN202211686308.7A CN202211686308A CN116270922B CN 116270922 B CN116270922 B CN 116270922B CN 202211686308 A CN202211686308 A CN 202211686308A CN 116270922 B CN116270922 B CN 116270922B
- Authority
- CN
- China
- Prior art keywords
- parts
- resolving
- prescription
- turbidity
- arthralgia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000006820 Arthralgia Diseases 0.000 title claims abstract description 31
- 230000001717 pathogenic effect Effects 0.000 title claims abstract description 16
- 244000052769 pathogen Species 0.000 title claims abstract description 12
- 201000005569 Gout Diseases 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 45
- 206010018634 Gouty Arthritis Diseases 0.000 claims abstract description 29
- 230000001684 chronic effect Effects 0.000 claims abstract description 26
- 239000008280 blood Substances 0.000 claims abstract description 23
- 210000004369 blood Anatomy 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 240000004274 Sarcandra glabra Species 0.000 claims abstract description 9
- 210000000582 semen Anatomy 0.000 claims abstract description 4
- 210000000952 spleen Anatomy 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- 206010062717 Increased upper airway secretion Diseases 0.000 claims description 11
- 208000026435 phlegm Diseases 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 206010003246 arthritis Diseases 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 230000003907 kidney function Effects 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 25
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 25
- 229940116269 uric acid Drugs 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 17
- 239000000203 mixture Substances 0.000 abstract description 10
- 208000024891 symptom Diseases 0.000 abstract description 9
- 241000522190 Desmodium Species 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 description 33
- 208000002193 Pain Diseases 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 208000004880 Polyuria Diseases 0.000 description 7
- 230000035619 diuresis Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 238000002203 pretreatment Methods 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- 244000281702 Dioscorea villosa Species 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 244000077995 Coix lacryma jobi Species 0.000 description 5
- 240000009022 Smilax rotundifolia Species 0.000 description 5
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 210000001503 joint Anatomy 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 210000002435 tendon Anatomy 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 241000241550 Cyathula Species 0.000 description 4
- 201000001431 Hyperuricemia Diseases 0.000 description 4
- 241000972673 Phellodendron amurense Species 0.000 description 4
- 235000007212 Verbena X moechina Moldenke Nutrition 0.000 description 4
- 240000001519 Verbena officinalis Species 0.000 description 4
- 235000001594 Verbena polystachya Kunth Nutrition 0.000 description 4
- 235000007200 Verbena x perriana Moldenke Nutrition 0.000 description 4
- 235000002270 Verbena x stuprosa Moldenke Nutrition 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 244000161999 Acacia greggii Species 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 235000004608 catclaw acacia Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000030194 mouth disease Diseases 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 101001109465 Homo sapiens NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241001571764 Lysimachia christinae Species 0.000 description 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 1
- 244000076686 Queensland pidgeon grass Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000736026 Sarcandra Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 235000003232 Setaria pumila ssp. pallide fusca Nutrition 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- 235000019654 spicy taste Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 235000019648 warmth Nutrition 0.000 description 1
Abstract
The invention discloses a prescription for eliminating turbid pathogen, resolving masses and removing arthralgia and application thereof, which is prepared from the following raw materials in parts by weight: 1-3 parts of rhizoma atractylodis, 2-8 parts of rhizoma smilacis glabrae, 1-3 parts of cortex phellodendri, 2-6 parts of semen coicis, 2-4 parts of glabrous sarcandra herb, 1-3 parts of rhizoma dioscoreae septemlobae, 2-4 parts of desmodium, 2-4 parts of radix ranunculi ternati, 1-3 parts of herba verbenae and 1-3 parts of radix cyathulae. The traditional Chinese medicine composition disclosed by the invention has satisfactory curative effects on treating chronic gouty arthritis by virtue of a prescription for resolving turbidity, resolving masses and removing arthralgia, and has the advantages compared with gouty and ning in the aspect of improving the traditional Chinese medicine symptoms of blood uric acid and chronic gout of patients.
Description
Technical Field
The invention particularly relates to a prescription for resolving turbidity, resolving masses and removing arthralgia and application thereof.
Background
Gout is a metabolic disease caused by increased uric acid production and/or decreased uric acid excretion due to purine metabolic disorder, and hyperuricemia is the basis of the disease. According to the 2018 European anti-rheumatic alliance gout diagnosis evidence-based proposal, the natural course of gout is basically divided into a preclinical stage (asymptomatic hyperuricemia stage) and a clinical stage (gouty arthritis attack stage, attack interval and chronic gouty arthritis stage). Most patients are shifted to the period of chronic arthritis after a plurality of acute attacks, the main clinical characteristics are that tophus formation or joint swelling and pain symptoms are continuously and cannot be relieved, the period is long, the disease is easy to repeat, the lasting is difficult to heal, the life health and the life quality of the patients are seriously influenced, and development and timely effective treatment are needed.
At present, most of clinical treatments of the Western medicine aiming at the chronic gouty arthritis are combined medicines, and uric acid reducing and anti-inflammatory analgesic medicines are required to be taken simultaneously, so that the compliance of patients is greatly reduced due to adverse drug reactions; the traditional Chinese medicine is the treasure of China, and plays an irreplaceable role in preventing and curing diseases for thousands of years by virtue of simple and convenient inspection. In the treatment of chronic gouty arthritis, the traditional Chinese medicine has the advantages of overall regulation, uric acid reduction, anti-inflammatory and analgesic effects, high safety and wide application prospect.
Wang Jianhui et al, based on the anti-inflammatory effect and aging study of NALP3 inflammable body-based gouty out-of-mouth disease on acute gouty arthritis rats [ J ], journal of Chinese medicinal information, 2020 (01) discloses a prescription consisting of 10 traditional Chinese medicines of glabrous greenbrier rhizome, rhizoma Dioscoreae Septemlobae, glabrous sarcandra herb and the like, namely gouty out-mouth disease out-of-mouth disease, has the effect of treating gouty arthritis. Clinical observation shows that the curative effect of the Chinese medicinal composition has room for further improvement so as to enhance the compliance of gouty arthritis patients on the Chinese medicinal prescription.
Disclosure of Invention
In order to solve the problems, the invention provides a prescription for eliminating turbid pathogen, resolving masses and removing arthralgia, which is prepared from the following raw materials in parts by weight:
1-3 parts of rhizoma atractylodis, 2-8 parts of rhizoma smilacis glabrae, 1-3 parts of cortex phellodendri, 2-6 parts of semen coicis, 2-4 parts of glabrous sarcandra herb, 1-3 parts of rhizoma dioscoreae septemlobae, 2-4 parts of desmodium, 2-4 parts of radix ranunculi ternati, 1-3 parts of herba verbenae and 1-3 parts of radix cyathulae.
Further, the traditional Chinese medicine is prepared from the following raw materials in parts by weight:
1 part of rhizoma atractylodis, 3 parts of rhizoma smilacis glabrae, 1 part of cortex phellodendri, 3 parts of semen coicis, 3 parts of glabrous sarcandra herb, 2 parts of rhizoma dioscoreae septemlobae, 3 parts of herba lysimachiae, 3 parts of radix ranunculi ternati, 2 parts of herba verbenae and 2 parts of radix cyathulae.
Further, the preparation is prepared by taking fine powder of the raw material medicine or water extract or alcohol extract of the raw material medicine as an active ingredient and adding pharmaceutically acceptable auxiliary materials.
Still further, the formulation is an oral formulation.
Still further, the oral formulation is a solution, granule, pill, paste or tablet.
The invention also provides a preparation method of the prescription for eliminating turbid pathogen, resolving masses and removing arthralgia, which comprises the following steps:
(1) Weighing the raw materials according to the proportion;
(2) Grinding the raw materials into powder, or extracting with water or organic solvent, and adding pharmaceutically acceptable adjuvants or auxiliary components.
The invention finally provides application of the prescription for eliminating turbid pathogen, resolving masses and removing arthralgia in preparing medicines for treating arthritis.
Further, the medicament is a medicament for treating gouty arthritis.
Further, the medicament is a medicament for treating chronic gouty arthritis.
Further, the medicine is a medicine for treating spleen deficiency damp-heat phlegm turbidity and stasis type chronic gouty arthritis.
The invention provides a gout 'internal dampness induced arthralgia' theory based on the summary of clinical practice experience for years in the early stage, and creates a proved recipe of treating arthralgia, namely, gout, which is good at clearing internal dampness under the guidance of the theory, has remarkable effect on hyperuricemia and acute gouty arthritis, and discloses a mechanism of reducing uric acid and inhibiting acute gout inflammatory reaction of the recipe through a series of basic research parts. The invention further provides the pathogenesis recognition of the spleen deficiency and damp-heat phlegm turbidity stasis accumulation in combination with the clinical feedback of gout and the traditional Chinese medicine syndrome characteristics of chronic gouty arthritis under the theoretical guidance of the early stage of internal dampness arthralgia, and provides the traditional Chinese medicine prescription of turbidity-resolving and stagnation-resolving arthralgia-removing formula with the effects of strengthening spleen, promoting diuresis, eliminating turbidity, clearing heat, eliminating phlegm and promoting blood circulation.
The method of the invention is shown in the recipe, and ancient sayings of the method is carried out along with the syndrome of the first aspect, the Chinese atractylodes is mainly used for pungent and bitter taste and warmth, entering the liver channel of the spleen and stomach, strengthening the spleen and eliminating dampness, and the spleen is used for eliminating turbid dampness so as to remove the source of dampness; rhizoma smilacis glabrae has sweet and light taste, enters liver and stomach meridians, has the effects of removing dampness and promoting diuresis, and activating and benefiting joints, and also has the effect of strengthening spleen, and is a Chinese medicine of Ben Cao gang mu: "strengthening spleen and stomach, strengthening tendons and bones, dispelling pathogenic wind and dampness, and benefiting joints"; the two herbs are combined together, so they are commonly used as monarch drugs. With the assistance of Huang Baiwei bitter and cold, entering kidney and bladder meridians, it is good at clearing heat and drying dampness; coix seed is sweet bland nature in taste and cool, enters spleen, stomach and lung channels, promotes diuresis and excretes dampness, removes arthralgia and dissipates stagnation, and strengthens spleen qi, and the "materia Medica dredging" is as follows: the nature can remove dampness, the taste is sweet, the spleen can be reinforced, and the spleen can be leaked by bland, so that the main tendons are urgent, the muscles and tendons can not flex and stretch, the wind-damp arthralgia, and the pathogenic qi of tendons and bones can not be removed by … …; the sarcandra has the characteristics of pungent and bitter flavor, returns to heart and liver meridian, has the functions of activating blood, removing obstruction in collaterals, relieving swelling and pain, and is carried in the medicine property of classified herbs: the traditional Chinese medicine composition has a remarkable clinical effect on treating all rheumatic numbness and arthralgia, and has the effect on treating the swelling and pain of tendons and bones and the tuberosity caused by stagnation of turbid phlegm and stasis and incapacitation of each other, and the three medicines are all ministerial medicines. The yam rhizome is added with the bitter taste of the yam rhizome, enters kidney and stomach channels, promotes diuresis, eliminates turbid pathogen, dispels wind and eliminates arthralgia, and is recorded in the cloud of the compendium of materia medica: di Xie is good at dispelling wind-damp, so it can treat chronic and weak arthralgia … … due to wind-damp; herba Lysimachiae Christinae has sweet and salty nature and slight cold property, and enters liver, gallbladder, kidney and bladder channels, and has the characteristics of clearing heat and promoting diuresis, and eliminating pathogenic dampness and heat from urination; radix Ranunculi Ternati has sweet and spicy taste, and can enter liver and lung channels, resolve phlegm, soften hardness, dissipate stagnation and reduce swelling; herba Verbenae is bitter and cool in taste, enters liver and spleen meridians, promotes blood circulation to remove blood stasis, promotes diuresis and eliminates dampness, and the four ingredients have the effects of clearing heat and eliminating dampness, reducing phlegm and promoting blood circulation, and removing obstruction in collaterals and eliminating turbid pathogen. Radix Cyathulae is sweet and slightly bitter in taste and enters liver and kidney meridians, and has the effects of promoting joint circulation, promoting blood circulation, removing blood stasis, eliminating dampness and promoting urination, so that damp-heat blood stasis is removed from the bottom, and the radix cyathulae is an adjuvant drug. The whole formula has the effects of both cold and warm, strengthening vital qi to eliminate pathogenic factor, strengthening spleen and promoting diuresis, eliminating turbid pathogen, clearing heat and eliminating phlegm and promoting blood circulation.
Clinical observation experiments prove that: the Chinese medicinal preparation for treating the chronic gouty arthritis has satisfactory curative effects on treating the chronic gouty arthritis, and has the advantages of improving the blood uric acid of a patient and the traditional Chinese medicine symptoms of the chronic gout compared with gouty and calm.
It should be apparent that, in light of the foregoing, various modifications, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
The above-described aspects of the present invention will be described in further detail below with reference to specific embodiments in the form of examples. It should not be understood that the scope of the above subject matter of the present invention is limited to the following examples only. All techniques implemented based on the above description of the invention are within the scope of the invention.
Detailed Description
The materials and equipment used in the embodiments of the present invention are all known products and are obtained by purchasing commercially available products. The solution, pill, granule, paste and tablet prepared by the composition of the invention are prepared by mature preparation processes and refer to the conventional methods in the prior art.
Example 1 preparation of the composition of the invention-preparation of the prescription for resolving turbidity, resolving hard mass and removing arthralgia
The formula comprises the following components: 5g of rhizoma atractylodis, 15g of glabrous greenbrier rhizome, 5g of amur corktree bark, 15g of coix seed, 15g of glabrous sarcandra herb, 10g of yam rhizome, 15g of desmodium, 15g of catclaw grass, 10g of verbena and 10g of medicinal cyathula root;
The preparation method comprises the following steps: weighing the raw materials according to the proportion, adding 10 times of water, decocting for 2 times each for 30 minutes, filtering, and combining the filtrates.
EXAMPLE 2 preparation of the composition of the invention, the preparation of the prescription for resolving turbidity, resolving hard mass and removing arthralgia
The formula comprises the following components: 5g of rhizoma atractylodis, 10g of glabrous greenbrier rhizome, 5g of amur corktree bark, 10g of coix seed, 10g of glabrous sarcandra herb, 5g of yam rhizome, 10g of desmodium, 10g of catclaw grass, 5g of verbena and 5g of medicinal cyathula root;
The preparation method comprises the following steps: weighing the raw materials according to the proportion, adding 8 times of water, decocting for 2 times each for 30 minutes, filtering, and combining the filtrates.
EXAMPLE 3 preparation of the composition of the invention, the preparation of the prescription for resolving turbidity, resolving hard mass and removing arthralgia
The formula comprises the following components: 10g of rhizoma atractylodis, 40g of glabrous greenbrier rhizome, 10g of amur corktree bark, 30g of coix seed, 20g of glabrous sarcandra herb, 15g of yam rhizome, 20g of desmodium, 20g of catclaw grass, 15g of verbena and 15g of medicinal cyathula root;
The preparation method comprises the following steps: weighing the raw materials according to the proportion, adding 12 times of water, decocting for 3 times each for 20 minutes, filtering, and combining the filtrates.
The advantageous effects of the present invention are described below by way of test examples.
Experimental example 1 clinical observation study
1. Clinical data
1.1 Diagnostic criteria
Is formulated with reference to the Chinese medical society rheumatology division, primary gout diagnosis and treatment guide [11].
1.2 Inclusion criteria
① Meets the Western diagnosis standard of the chronic gouty arthritis, and is suitable for men with ages of 18-65 years;
② Voluntary attends and signs informed consent.
1.3 Exclusion criteria
① Patients with rheumatoid arthritis, osteoarthritis or severe joint deformity; ② Patients with mental illness, senile dementia and the like can not cooperate with the traditional Chinese medicine; ③ Patients with serious diseases such as cardiovascular and cerebrovascular diseases, liver diseases, renal diseases, hematopoietic system diseases, etc.; the curative effect or safety judgment is not affected by the prescribed medication or incomplete data.
1.4 General data
100 Cases of male chronic gouty arthritis patients were all collected from the Fujian traditional Chinese medicine university Hospital and the Fujian traditional Chinese medicine university affiliated third people hospital. The patients are randomly divided into 50 groups of observation groups and control groups, the ages of the observation groups are 42.40+/-1.43 years, the average ages of the control groups are 42.48 +/-1.56 years, and the general data comparison differences of the two groups of patients have no statistical significance (P > 0.05) and are comparable.
2. Method of
2.1 Case grouping
Study subjects were divided into observation and control groups of 50 cases each using a randomized controlled protocol.
2.2 Methods of treatment
The observation group is prepared from 5g of rhizoma atractylodis, 15g of glabrous greenbrier rhizome, 5g of amur corktree bark, 15g of coix seed, 15g of glabrous sarcandra herb, 10g of yam rhizome, 15g of lysimachia christinae, 15g of cattail grass, 10g of verbena and 10g of medicinal cyathula root, and is decocted with water for taking 1 dose per day, and is taken separately in the morning and evening.
The control group is for treating gout, and is prepared from rhizoma Smilacis Glabrae 15g, rhizoma Dioscoreae Septemlobae 9g, herba Pileae Scriptae 10g, radix Cyathulae 10g, radix Gentianae Marcrophyllae 10g, saviae Miltiorrhizae radix 15g, alismatis rhizoma 10g, herba Desmodii Styracifolii 15g, rhizoma Atractylodis 6g, cortex Phellodendri 6g, by decocting with water, 1 dose daily, and administering in the morning and evening.
High purine diets were avoided during the dosing period. The 2 groups of patients all take the medicine continuously for 8 weeks.
2.3 Observation index and method
2.3.1 Detection of blood Uric Acid (UA) levels
Venous blood is sampled for UA after treatment and before and after treatment, and after 1 and 2 weeks of treatment.
2.3.2 Detection of blood sedimentation (ESR), creatinine (Cr) level
Vein blood is drawn on an empty stomach before and after treatment to detect ESR and Cr.
2.3.3 Visual Analog Scoring (VAS)
Before and after treatment, VAS is adopted for evaluation, 1 vernier caliper marked with 0-10 scales is used, each digital distance is equally divided, 0 point represents no pain, 10 points represent the most intense pain, the patient is marked with the corresponding position capable of representing the pain degree of the patient on the caliper, and a doctor evaluates the mark according to the marked position of the patient. The score is 0-10, the higher the score the more severe the pain.
2.3.4 Chinese medical Condition scoring
The symptoms of joint swelling, joint pain, joint soreness, limb heaviness, listlessness, loose stool, scanty urine, sticky mouth and thirst and tongue fur pulse conditions of a patient before and after treatment are evaluated by referring to the diagnosis basis of gout, syndrome classification and curative effect evaluation [13]. See table 1.
Table 1 evaluation of the symptoms of Chinese traditional medicine
2.4 Statistical methods
ˉ
SPSS 25.0 software was used for data processing. The data of the measurement are in accordance with normal distribution and are expressed by (X+/-s), the comparison in the groups adopts paired t test, and the comparison between the groups adopts grouped t test. P < 0.05 indicates that the difference is statistically significant.
3 Results
3.1 Comparison of blood uric acid levels in groups 1, 2 weeks before and after treatment
There was no significant difference in blood uric acid levels (P > 0.05) in the pre-treatment 2 groups of patients; after treatment, at week 1 and week 2 after the end of treatment, the average of 2 groups of haematuria is lower than before treatment (P is less than 0.05); comparing between groups, observing that the blood uric acid level of the 2 nd week after the treatment of the group is lower than that of the contemporaneous control group (P is less than 0.05). See Table 2
TABLE 2 comparison of blood uric acid levels before and after treatment, group 1, 2 weeks 2
Note that: a P < 0.05 compared to pre-treatment; b P < 0.05 compared to the contemporaneous control.
3.2 Comparison of ESR and Cr levels in groups 2 before and after treatment
There was no significant difference in ESR, cr (P > 0.05) in the pre-treatment 2 groups of patients. Compared in the treated group, the ESR and Cr of the control group and the observed group are obviously reduced (P is less than 0.05); there was no significant difference in ESR, cr (P > 0.05) between the control and observed groups compared after treatment. See Table 3
TABLE 3 comparison of ESR and Cr levels in groups 2 before and after treatment
Note that: a P < 0.05 compared to pre-treatment.
3.3 Comparison of VAS scores of 2 groups before and after treatment
There was no significant difference in VAS scores (P > 0.05) for the pre-treatment 2 groups of patients. Post-treatment in-group comparison, control and observed groups showed a significant decrease in VAS score (P < 0.05); there was no significant difference in VAS scores (P > 0.05) between the control and the observed groups compared after treatment. See Table 4
Table 4 comparison of the VAS scores of the 2 groups before and after treatment
Note that: a P < 0.05 compared to pre-treatment.
3.4 Comparison of scores of 2 groups of Chinese medical Condition before and after treatment
There was no significant difference in the scores of the traditional Chinese medicine syndromes in the 2 groups before treatment (P > 0.05). The traditional Chinese medicine syndrome score of the control group and the observation group is obviously lower than that before treatment (P is less than 0.05) compared in the treatment group; the comparison between the groups after treatment shows that the traditional Chinese medicine syndrome score of the observed group is obviously lower than that of the control group (P is less than 0.05). See Table 5
Table 5 comparison of scores of 2 groups of chinese medical conditions before and after treatment
Note that: a P < 0.05 compared to pre-treatment; b P < 0.05 compared to the contemporaneous control.
Discussion 4
It is found that the blood uric acid level is proportional to the gout arthritis attack rate, with the rise of the blood uric acid level, the arthritis attack is more frequent, the intermittent period is shorter and shorter, the pain is gradually aggravated, even the pain cannot be completely relieved after the attack, the affected joints are gradually increased, and the affected joints develop from the previous feet to the joints such as shoulders, the spine, the mandible and the like. Further studies have found that the deposition rate of tophus is also related to the extent and duration of hyperuricemia, with blood uric acid levels being the primary determinant. Gutman found that the average blood uric acid concentration was 9.1mg/dL in 722 painless tophus patients, 10-12 mg/dL in 456 patients with low to medium tophus, and more than 11mg/dL in 11 patients with broad tophus. The higher the blood uric acid level, the longer the duration, the more likely the gout is repeatedly started and tophus is formed, so the continuous and stable control of the blood uric acid level is the key point of the prevention and treatment work of the chronic gouty arthritis.
The research results prove that the prescription for eliminating turbid pathogen, resolving masses and removing arthralgia and the gout medicine both have the effects of obviously reducing uric acid, relieving gout arthritis pain and improving Chinese medicine symptoms, and the prescription for eliminating turbid pathogen, resolving masses and removing arthralgia is more obvious than the gout medicine in improving Chinese medicine symptoms related to chronic gouty arthritis, and is more compatible with the pathogenesis characteristics of spleen deficiency, damp-heat, phlegm turbidity and stasis of the chronic gouty arthritis; the follow-up at the 2 nd week after the treatment is finished further finds that the prescription has an advantage in the aspect of continuously and stably reducing uric acid compared with gouty, and is more suitable for the treatment of the chronic stage.
In conclusion, the prescription for resolving turbidity, resolving masses and removing arthralgia, which is established aiming at the characteristics of the spleen deficiency and damp-heat phlegm-turbidity stasis syndrome of the chronic gouty arthritis and is characterized by the pathogenesis of the chronic gouty arthritis, can obviously reduce the blood uric acid level of the chronic gouty arthritis patient, lighten the inflammation and pain degree of the chronic gouty arthritis patient, improve the traditional Chinese medicine symptoms, protect the kidney function, and is superior to gouty tannin in improving the blood uric acid of the patient and the traditional Chinese medicine symptoms of the chronic gouty arthritis, has better effect of maintaining uric acid reduction, and is worthy of popularization and application.
Claims (9)
1. A prescription for resolving turbidity, resolving masses and removing arthralgia with the functions of treating spleen deficiency, damp-heat, phlegm turbidity and blood stasis and intertwined chronic gouty arthritis and protecting kidney functions is characterized in that: the traditional Chinese medicine is prepared from the following raw materials in parts by weight:
1 part of rhizoma atractylodis, 3 parts of rhizoma smilacis glabrae, 1 part of cortex phellodendri, 3 parts of semen coicis, 3 parts of glabrous sarcandra herb, 2 parts of rhizoma dioscoreae septemlobae, 3 parts of herba lysimachiae, 3 parts of radix ranunculi ternati, 2 parts of herba verbenae and 2 parts of radix cyathulae.
2. The prescription for resolving turbidity, resolving masses and removing arthralgia according to claim 1, which is characterized in that: the preparation is prepared from fine powder of raw materials, or water extract or alcohol extract of raw materials as active ingredients, and pharmaceutically acceptable auxiliary materials.
3. The prescription for resolving turbidity, resolving masses and removing arthralgia according to claim 2, which is characterized in that: the preparation is an oral preparation.
4. The prescription for resolving turbidity, resolving masses and removing arthralgia according to claim 3, which is characterized in that: the oral preparation is solution, granule, pill, paste or tablet.
5. A method for preparing the prescription for eliminating turbid pathogen, resolving masses and removing arthralgia according to any one of claims 1 to 4, which is characterized in that: it comprises the following steps:
(1) Weighing the raw materials according to the proportion;
(2) Grinding the raw materials into powder, or extracting with water or organic solvent, and adding pharmaceutically acceptable adjuvants or auxiliary components.
6. The use of the turbidity-resolving, stagnation-resolving and arthralgia-removing formula according to any one of claims 1-4 in preparing a medicament for treating arthritis.
7. Use according to claim 6, characterized in that: the medicine is used for treating gouty arthritis.
8. Use according to claim 7, characterized in that: the medicine is used for treating chronic gouty arthritis.
9. Use according to claim 8, characterized in that: the medicine is used for treating spleen deficiency damp-heat phlegm turbidity and stasis type chronic gouty arthritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211686308.7A CN116270922B (en) | 2022-12-27 | Prescription for eliminating turbid pathogen, resolving masses and removing arthralgia and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211686308.7A CN116270922B (en) | 2022-12-27 | Prescription for eliminating turbid pathogen, resolving masses and removing arthralgia and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116270922A CN116270922A (en) | 2023-06-23 |
| CN116270922B true CN116270922B (en) | 2024-04-19 |
Family
ID=
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814220A (en) * | 2005-11-23 | 2006-08-09 | 安徽省药物研究所 | Medicine for treating gout and preparing method |
| CN104524419A (en) * | 2015-01-16 | 2015-04-22 | 邓运明 | Traditional Chinese medicine preparation for treating gout |
| CN107184881A (en) * | 2017-04-26 | 2017-09-22 | 宁波神能保健器材有限公司 | Treat Chinese medicine of gout and preparation method thereof |
| CN108210804A (en) * | 2018-02-06 | 2018-06-29 | 郭涤尘 | A kind of gout Nieron Capsules and preparation method thereof |
| CN112755140A (en) * | 2021-02-23 | 2021-05-07 | 成都医学院 | Pharmaceutical composition for treating gouty arthritis and preparation method and application thereof |
| CN114028511A (en) * | 2021-12-17 | 2022-02-11 | 南京中医药大学 | Traditional Chinese medicine composition for treating intractable gout and application thereof |
| CN114632128A (en) * | 2022-03-24 | 2022-06-17 | 王国辉 | Collateral-dredging and turbid-removing formula and using method thereof |
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814220A (en) * | 2005-11-23 | 2006-08-09 | 安徽省药物研究所 | Medicine for treating gout and preparing method |
| CN104524419A (en) * | 2015-01-16 | 2015-04-22 | 邓运明 | Traditional Chinese medicine preparation for treating gout |
| CN107184881A (en) * | 2017-04-26 | 2017-09-22 | 宁波神能保健器材有限公司 | Treat Chinese medicine of gout and preparation method thereof |
| CN108210804A (en) * | 2018-02-06 | 2018-06-29 | 郭涤尘 | A kind of gout Nieron Capsules and preparation method thereof |
| CN112755140A (en) * | 2021-02-23 | 2021-05-07 | 成都医学院 | Pharmaceutical composition for treating gouty arthritis and preparation method and application thereof |
| CN114028511A (en) * | 2021-12-17 | 2022-02-11 | 南京中医药大学 | Traditional Chinese medicine composition for treating intractable gout and application thereof |
| CN114632128A (en) * | 2022-03-24 | 2022-06-17 | 王国辉 | Collateral-dredging and turbid-removing formula and using method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1840154A (en) | Ointment for treating nervous damage and preparation method thereof | |
| CN104815318A (en) | Traditional Chinese medicine preparation for treating gout | |
| CN116139237B (en) | A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application | |
| CN103341092A (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN116270922B (en) | Prescription for eliminating turbid pathogen, resolving masses and removing arthralgia and application thereof | |
| CN107468768B (en) | Qiang medicine composition and application thereof | |
| CN116270922A (en) | Prescription for eliminating turbid pathogen, resolving masses and removing arthralgia and application thereof | |
| CN108619427B (en) | Pain-relieving and acid-reducing herb tea for preventing and treating gouty arthritis | |
| CN103285284A (en) | Medical composition for treating senile vaginitis | |
| CN103301353A (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN114028511B (en) | Traditional Chinese medicine composition for treating intractable gout and application thereof | |
| CN112972559B (en) | Traditional Chinese medicine composition and traditional Chinese medicine mixture for treating bone and soft tissue suppurative inflammation | |
| CN116350731B (en) | Formula for clearing heat, removing dampness and relieving arthralgia as well as preparation and application thereof | |
| CN103656380A (en) | Medicine for treating Parkinson's disease | |
| CN115770279B (en) | Traditional Chinese medicine composition for treating chronic lower limb vein diseases, decoction and preparation thereof | |
| CN109999155B (en) | Traditional Chinese medicine composition for treating Alzheimer disease and preparation method thereof | |
| CN109602875B (en) | Traditional Chinese medicine composition for treating infantile fever as well as preparation method and application thereof | |
| CN114588242B (en) | Pharmaceutical composition for treating rheumatoid arthritis | |
| CN112138105B (en) | Traditional Chinese medicine composition for treating bronchiectasis lung-spleen qi deficiency and phlegm-damp lung blocking syndrome and application thereof | |
| CN114588233B (en) | Composition for treating acute gout | |
| CN108524658B (en) | Traditional Chinese medicine for treating restless legs syndrome and preparation method thereof | |
| CN109758505B (en) | Traditional Chinese medicine composition for treating gouty arthritis and preparation method and application thereof | |
| CN108578549B (en) | Medicine for treating acne and application thereof | |
| CN105943700A (en) | Traditional Chinese medicine composition capable of tonifying kidney and relieving paralysis and preparation method and application thereof | |
| CN1544068A (en) | Antigout medicinal composition and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |